Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › AML

AML

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for AML

16 trials tracked for AML: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 478 citations.

16Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 11 Phase 1 2 Other / NA 1
  1. Phase 3 (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive Completed · 478 cited
  2. Phase 3 Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) Completed · 211 cited
  3. Phase 2 Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) Completed
  4. Phase 2 A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) Completed
  5. Phase 2 Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT Completed
  6. Phase 2 Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies Completed
Show 10 more trials
  1. Phase 2 A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia Completed
  2. Phase 2 Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD Completed
  3. Phase 2 SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Completed
  4. Phase 2 Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) Completed
  5. Phase 2 Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia Completed
  6. Phase 2 Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia Completed
  7. Phase 2 Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Completed
  8. Phase 1 Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function Completed
  9. Phase 1 A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status Completed
  10. N/A Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) Completed

Showing the 16 most-cited and recently-updated of 16 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Long-course venetoclax with hypomethylating agents in unfit AML patients shows stable efficacy and MRD prognostic value
Oncology Cohort
Long-course venetoclax with hypomethylating agents in unfit AML patients shows stable efficacy and MRD prognostic value Frail Leukemia Patients See Better Results With New Blood Monitoring
This single-center retrospective analysis evaluated long-course venetoclax combined with hypomethylating agents in unfit AML patients.
A new look at blood tests shows how well frail leukemia patients respond to standard treatment.
Frontiers Apr 21, 2026
AI tool predicts acute leukemia subtypes with AUROC 0.94 for AML, 0.98 for promyelocytic, 0.84 for ALL in international cohort
Oncology
AI tool predicts acute leukemia subtypes with AUROC 0.94 for AML, 0.98 for promyelocytic, 0.84 for ALL in international cohort Can a simple blood test help diagnose leukemia? An AI tool shows promise but still needs work
An AI tool was tested on a retrospective, international cohort of 6206 leukemia patients from 20 centers to predict acute leukemia subtypes …
An AI tool can spot leukemia from standard blood tests but must refuse to guess for most patients until doctors refine it to help more peopl…
Mar 30, 2026